<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197661</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-108</org_study_id>
    <nct_id>NCT04197661</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects</brief_title>
  <official_title>A Study Evaluating Pharmacokinetics, Pharmacodynamics and Safety of Intravenous Administration of HSK3486 Injectable Emulsion in Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a single-center, open-label, dose-finding, Phase I clinical study evaluating the&#xD;
      pharmacokinetics, pharmacodynamics, and safety characteristics of HSK3486 in healthy elderly&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 25, 2019</start_date>
  <completion_date type="Actual">May 22, 2020</completion_date>
  <primary_completion_date type="Actual">January 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>Cmax（a measure of the body's exposure to HSK3486）will be compared between non-elderly subjects and elderly subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve（AUC）</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>AUC（a measure of the body's exposure to HSK3486）will be compared between non-elderly subjects and elderly subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MOAA/S(modified observer's assessment of alert /sedation)</measure>
    <time_frame>-5 minutes before administration until 1 hours post administration on day 1</time_frame>
    <description>modified observer's assessment of alert /sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral index(BIS)</measure>
    <time_frame>-5 minutes before administration until 1 hours post administration on day 1</time_frame>
    <description>Bispectral index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>time to peak observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>Total clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure（systolic, diastolic and mean arterial pressure）</measure>
    <time_frame>from the screening to 2 days post-dose</time_frame>
    <description>safety endpoits</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Elderly Subjects</condition>
  <arm_group>
    <arm_group_label>Elderly groupⅠ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elderly groupⅠ 65 years or older 0.2 mg/kg HSK3486</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly group Ⅱ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elderly group Ⅱ 65 years or older 0.3 mg/kg HSK3486</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly group Ⅲ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elderly group Ⅲ 65 years or older 0.4 mg/kg HSK3486</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-elderly group IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-elderly group IV 18 to 64 years 0.4 mg/kg HSK3486</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.</description>
    <arm_group_label>Elderly groupⅠ</arm_group_label>
    <other_name>HSK3486 0.2 mg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.</description>
    <arm_group_label>Elderly group Ⅱ</arm_group_label>
    <other_name>HSK3486 0.3 mg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.</description>
    <arm_group_label>Elderly group Ⅲ</arm_group_label>
    <other_name>HSK3486 0.4 mg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.</description>
    <arm_group_label>Non-elderly group IV</arm_group_label>
    <other_name>HSK3486 0.4 mg/kg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign the informed consent form and fully understand the content, procedure and&#xD;
             possible adverse effects before the trial starts;&#xD;
&#xD;
          2. Able to complete the study in compliance with the requirements of the clinical trial&#xD;
             protocol;&#xD;
&#xD;
          3. Subjects (including their partners) are willing to voluntarily adopt an effective&#xD;
             measure of contraception starting from screening to 6 months after the last dose of&#xD;
             the investigational drug. See the attachment for specific contraceptive measures;&#xD;
&#xD;
          4. Males and females with full capacity for civil conduct, aged ≥ 18 years old (aged&#xD;
             between 18 and 64 years old for the non-elderly group and ≥ 65 years old for the&#xD;
             elderly group (inclusive));&#xD;
&#xD;
          5. Females weighing ≥ 45 kg and males weighing ≥ 50 kg, and with a body mass index (BMI)&#xD;
             of ≥ 18 and ≤ 30 kg/m2 (BMI = Weight (kg)/height2(m2))(inclusive);&#xD;
&#xD;
          6. For all subjects, the body temperature should be between 35.9-37.6 °C, respiratory&#xD;
             rate between 12-20 breaths/min, and SpO2 when inhaling &gt; 95%; in addition, for&#xD;
             subjects in the non-elderly group, the blood pressure should be between 90-140/60-90&#xD;
             mmHg and heart rate between 60-99 bpm; for those in the elderly group, the blood&#xD;
             pressure should be between 90-160/60-100 mmHg and heart rate between 50-100 bpm;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Smoke more than 5 cigarettes per day on average within 3 months prior to screening;&#xD;
&#xD;
          2. Patient having contraindications to deep sedation/general anesthesia or a history of&#xD;
             past sedation/anesthesia accidents;&#xD;
&#xD;
          3. Known sensitivity to HSK3486 excipients (soybean oil, glycerin, triglyceride, egg&#xD;
             lecithin, sodium oleate, and sodium hydroxide); or history of drug allergies&#xD;
             (including other anesthetics), allergic diseases, or those with hyperactive&#xD;
             immuneresponse(allergies to various drugs and foods);&#xD;
&#xD;
          4. History of drug abuse or any signs of long-term use of benzodiazepines (such as&#xD;
             insomnia, anxiety, spasms) within 3 months prior to screening;&#xD;
&#xD;
          5. Acute diseases with clinical significance (determined by the investigator) within 2&#xD;
             weeks prior to screening, including GI diseases and infections (such as respiratory or&#xD;
             CNS infections);&#xD;
&#xD;
          6. History or evidence of cardiovascular diseases prior to screening: Uncontrolled&#xD;
             hypertension [SBP ≥ 170 mmHg and/or DBP ≥ 105 mmHg without antihypertensive treatment,&#xD;
             or SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg despite antihypertensive treatment], postural&#xD;
             hypotension, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina,&#xD;
             myocardial infarction within 6 months before screening, history of&#xD;
             tachycardia/bradycardia requiring medication, II-III degree atrioventricular block&#xD;
             (excluding patients with pacemakers), or QTcF interval ≥ 450 ms (Fridericia's&#xD;
             correction formula);&#xD;
&#xD;
          7. Subjects judged by the investigator to be unsuitable for participating in this trial&#xD;
             for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhua Ding, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Phase I Clinical Trial Laboratory，The First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phase I Clinical Trial Laboratory, The First Hospital of Jilin University</name>
      <address>
        <city>Chang chun</city>
        <state>Ji Lin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Qin L, Ren L, Wan S, Liu G, Luo X, Liu Z, Li F, Yu Y, Liu J, Wei Y. Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General Anesthetics. J Med Chem. 2017 May 11;60(9):3606-3617. doi: 10.1021/acs.jmedchem.7b00254. Epub 2017 Apr 28.</citation>
    <PMID>28430430</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Elderly Subjects</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

